UNSPSC 51171634: Alvimopan

This classification denotes an opiate antagonist with the molecular formula C25H32N2O4.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 677C126AET, chemically known as glycine, n-((2s)-2-(((3r,4r)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-, dihydrate but generally known as alvimopan, which bears US NIH Compound Identifier 5488547. Alvimopan most often comes in simple, anhydrous, and hyrdate forms.

UNSPSC 51171634 Alvimopan is a Commodity code that does not align with the recent state and local procurement activity posted under it. The three opportunities in the source—offender specimen collection and drug testing services (Collin County), direct-to-manufacturer prescription programs (Texas HHS), and generic multi-source pharmaceuticals via cooperative purchasing (MMCAP)—address clinical laboratory testing, pharmacy benefit management, and pharmaceutical supply chain logistics respectively. None involve alvimopan, a GI motility agent used in postoperative ileus treatment. The code appears to be a misclassification in the state and local taxonomy, or the opportunities have been tagged incorrectly.

The mismatch limits actionable intelligence for this specific code. If your firm pursues pharmaceutical or clinical laboratory services for state and local buyers, the three posted opportunities offer relevant market signals: Collin County Community Supervision and Corrections Department is contracting for drug testing services (RFP 2026-327, due July 23, 2026, estimated $600,000 over two years with renewal options); Texas HHS issued a market-research RFI (HHS0017013, deadline April 3, 2026) to explore direct-to-manufacturer prescription relationships; and MMCAP, administered by Minnesota Department of Administration, is aggregating generic pharmaceutical and OTC product sourcing across multiple state and local jurisdictions (RFP S1070000015802, due March 26, 2026, contract effective July 1, 2026). These reflect broader state procurement interest in pharmacy cost management and specimen testing infrastructure, but they do not correspond to alvimopan procurement specifically.